Seek Returns logo

GH vs. IQV: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at GH and IQV, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolGHIQV
Company NameGuardant Health, Inc.IQVIA Holdings Inc.
CountryUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS IndustryHealth Care Providers & ServicesLife Sciences Tools & Services
Market Capitalization8.15 billion USD34.10 billion USD
ExchangeNasdaqGSNYSE
Listing DateOctober 4, 2018May 9, 2013
Security TypeCommon StockCommon Stock

Historical Performance

This chart compares the performance of GH and IQV by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

GH vs. IQV: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolGHIQV
5-Day Price Return6.28%-1.83%
13-Week Price Return27.98%23.81%
26-Week Price Return55.45%19.63%
52-Week Price Return205.95%-10.99%
Month-to-Date Return4.55%5.61%
Year-to-Date Return113.81%2.08%
10-Day Avg. Volume2.25M1.49M
3-Month Avg. Volume2.47M1.79M
3-Month Volatility52.89%48.37%
Beta1.591.37

Profitability

Return on Equity (TTM)

GH

-246.60%

Health Care Providers & Services Industry

Max
24.86%
Q3
15.79%
Median
8.56%
Q1
5.75%
Min
-1.64%

GH has a negative Return on Equity of -246.60%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

IQV

19.96%

Life Sciences Tools & Services Industry

Max
19.96%
Q3
11.51%
Median
6.47%
Q1
3.86%
Min
-6.95%

In the upper quartile for the Life Sciences Tools & Services industry, IQV’s Return on Equity of 19.96% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

GH vs. IQV: A comparison of their Return on Equity (TTM) against their respective Health Care Providers & Services and Life Sciences Tools & Services industry benchmarks.

Net Profit Margin (TTM)

GH

-49.93%

Health Care Providers & Services Industry

Max
11.56%
Q3
5.45%
Median
2.83%
Q1
1.13%
Min
-1.71%

GH has a negative Net Profit Margin of -49.93%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

IQV

7.88%

Life Sciences Tools & Services Industry

Max
32.18%
Q3
18.30%
Median
10.19%
Q1
4.20%
Min
-2.05%

IQV’s Net Profit Margin of 7.88% is aligned with the median group of its peers in the Life Sciences Tools & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.

GH vs. IQV: A comparison of their Net Profit Margin (TTM) against their respective Health Care Providers & Services and Life Sciences Tools & Services industry benchmarks.

Operating Profit Margin (TTM)

GH

-54.54%

Health Care Providers & Services Industry

Max
19.08%
Q3
9.66%
Median
4.77%
Q1
2.46%
Min
-0.83%

GH has a negative Operating Profit Margin of -54.54%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

IQV

13.85%

Life Sciences Tools & Services Industry

Max
38.39%
Q3
21.40%
Median
13.57%
Q1
8.38%
Min
-3.51%

IQV’s Operating Profit Margin of 13.85% is around the midpoint for the Life Sciences Tools & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.

GH vs. IQV: A comparison of their Operating Profit Margin (TTM) against their respective Health Care Providers & Services and Life Sciences Tools & Services industry benchmarks.

Profitability at a Glance

SymbolGHIQV
Return on Equity (TTM)-246.60%19.96%
Return on Assets (TTM)-29.04%4.50%
Net Profit Margin (TTM)-49.93%7.88%
Operating Profit Margin (TTM)-54.54%13.85%
Gross Profit Margin (TTM)62.84%34.25%

Financial Strength

Current Ratio (MRQ)

GH

3.71

Health Care Providers & Services Industry

Max
2.00
Q3
1.51
Median
1.29
Q1
0.92
Min
0.14

GH’s Current Ratio of 3.71 is exceptionally high, placing it well outside the typical range for the Health Care Providers & Services industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.

IQV

0.84

Life Sciences Tools & Services Industry

Max
3.46
Q3
2.78
Median
1.91
Q1
1.53
Min
0.43

IQV’s Current Ratio of 0.84 falls into the lower quartile for the Life Sciences Tools & Services industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

GH vs. IQV: A comparison of their Current Ratio (MRQ) against their respective Health Care Providers & Services and Life Sciences Tools & Services industry benchmarks.

Debt-to-Equity Ratio (MRQ)

GH

16.78

Health Care Providers & Services Industry

Max
2.29
Q3
1.24
Median
0.74
Q1
0.50
Min
0.00

With a Debt-to-Equity Ratio of 16.78, GH operates with exceptionally high leverage compared to the Health Care Providers & Services industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

IQV

2.68

Life Sciences Tools & Services Industry

Max
1.35
Q3
0.74
Median
0.41
Q1
0.18
Min
0.00

With a Debt-to-Equity Ratio of 2.68, IQV operates with exceptionally high leverage compared to the Life Sciences Tools & Services industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

GH vs. IQV: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Health Care Providers & Services and Life Sciences Tools & Services industry benchmarks.

Interest Coverage Ratio (TTM)

GH

-150.95

Health Care Providers & Services Industry

Max
14.47
Q3
7.50
Median
4.52
Q1
2.12
Min
-4.44

GH has a negative Interest Coverage Ratio of -150.95. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

IQV

3.68

Life Sciences Tools & Services Industry

Max
45.00
Q3
27.84
Median
7.16
Q1
2.12
Min
-14.08

IQV’s Interest Coverage Ratio of 3.68 is positioned comfortably within the norm for the Life Sciences Tools & Services industry, indicating a standard and healthy capacity to cover its interest payments.

GH vs. IQV: A comparison of their Interest Coverage Ratio (TTM) against their respective Health Care Providers & Services and Life Sciences Tools & Services industry benchmarks.

Financial Strength at a Glance

SymbolGHIQV
Current Ratio (MRQ)3.710.84
Quick Ratio (MRQ)3.190.81
Debt-to-Equity Ratio (MRQ)16.782.68
Interest Coverage Ratio (TTM)-150.953.68

Growth

Revenue Growth

GH vs. IQV: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

GH vs. IQV: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

GH

0.00%

Health Care Providers & Services Industry

Max
5.93%
Q3
2.59%
Median
1.35%
Q1
0.00%
Min
0.00%

GH currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

IQV

0.00%

Life Sciences Tools & Services Industry

Max
1.41%
Q3
0.65%
Median
0.35%
Q1
0.00%
Min
0.00%

IQV currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

GH vs. IQV: A comparison of their Dividend Yield (TTM) against their respective Health Care Providers & Services and Life Sciences Tools & Services industry benchmarks.

Dividend Payout Ratio (TTM)

GH

0.00%

Health Care Providers & Services Industry

Max
185.33%
Q3
74.82%
Median
36.00%
Q1
0.00%
Min
0.00%

GH has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

IQV

0.00%

Life Sciences Tools & Services Industry

Max
113.14%
Q3
61.34%
Median
17.74%
Q1
0.00%
Min
0.00%

IQV has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

GH vs. IQV: A comparison of their Dividend Payout Ratio (TTM) against their respective Health Care Providers & Services and Life Sciences Tools & Services industry benchmarks.

Dividend at a Glance

SymbolGHIQV
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

Price-to-Earnings Ratio (TTM)

GH

--

Health Care Providers & Services Industry

Max
40.02
Q3
29.75
Median
21.09
Q1
14.18
Min
7.05

P/E Ratio data for GH is currently unavailable.

IQV

27.64

Life Sciences Tools & Services Industry

Max
75.35
Q3
51.00
Median
32.93
Q1
25.27
Min
1.43

IQV’s P/E Ratio of 27.64 is within the middle range for the Life Sciences Tools & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

GH vs. IQV: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Health Care Providers & Services and Life Sciences Tools & Services industry benchmarks.

Price-to-Sales Ratio (TTM)

GH

9.91

Health Care Providers & Services Industry

Max
3.15
Q3
1.87
Median
0.74
Q1
0.27
Min
0.09

With a P/S Ratio of 9.91, GH trades at a valuation that eclipses even the highest in the Health Care Providers & Services industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.

IQV

2.18

Life Sciences Tools & Services Industry

Max
10.49
Q3
6.43
Median
4.66
Q1
2.88
Min
1.08

In the lower quartile for the Life Sciences Tools & Services industry, IQV’s P/S Ratio of 2.18 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.

GH vs. IQV: A comparison of their Price-to-Sales Ratio (TTM) against their respective Health Care Providers & Services and Life Sciences Tools & Services industry benchmarks.

Price-to-Book Ratio (MRQ)

GH

35.72

Health Care Providers & Services Industry

Max
7.33
Q3
4.45
Median
2.52
Q1
1.15
Min
0.66

At 35.72, GH’s P/B Ratio is at an extreme premium to the Health Care Providers & Services industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

IQV

4.72

Life Sciences Tools & Services Industry

Max
6.69
Q3
5.00
Median
3.46
Q1
2.38
Min
0.93

IQV’s P/B Ratio of 4.72 is within the conventional range for the Life Sciences Tools & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

GH vs. IQV: A comparison of their Price-to-Book Ratio (MRQ) against their respective Health Care Providers & Services and Life Sciences Tools & Services industry benchmarks.

Valuation at a Glance

SymbolGHIQV
Price-to-Earnings Ratio (TTM)--27.64
Price-to-Sales Ratio (TTM)9.912.18
Price-to-Book Ratio (MRQ)35.724.72
Price-to-Free Cash Flow Ratio (TTM)--17.01